STIMATE-MUSTN1

Across TCGA pan-cancer cohorts, STIMATE-MUSTN1 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of STIMATE-MUSTN1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where STIMATE-MUSTN1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types STIMATE-MUSTN1 is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

LIHC, LUSC, and LUAD are the cancer types where STIMATE-MUSTN1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in STIMATE-MUSTN1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.163	<.001	8	view →
LUSC	Male	All	−0.210	<.001	6	view →
LUAD	All	All	−0.149	<.001	6	view →
BRCA	Female	All	−0.116	<.001	6	view →
THCA	All	All	−0.081	.016	3	view →
UCEC	All	All	−0.180	.023	2	view →
KICH	All	All	−0.066	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

STIMATE-MUSTN1–LIHC

Open the LIHC breakdown →